This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Curis Announces Initiation Of A Clinical Trial Of CUDC-427 In Advanced Malignancies

Stocks in this article: CRIS

"We are excited to investigate CUDC-427 monotherapy using a continuous daily dosing regimen, which we believe has the potential to further enhance its anti-tumor activity as a single agent in difficult to treat cancers," said Ali Fattaey, Curis President and Chief Operating Officer. "Additionally, the expansion phase of this trial will further study CUDC-427's activity in patients with ovarian and fallopian tube cancers, where we expect to investigate CUDC-427 in patients with cancers of different genetic profiles, including patients with known gene mutations."

In addition to this Phase 1 trial, Curis is also planning to initiate clinical studies with CUDC-427 in patients with breast cancer and other malignancies. Curis is currently planning to initiate a clinical study evaluating the use of CUDC-427 in combination with capecitabine to treat HER2-negative breast cancer patients in 2013. The trial will be designed to initially determine the optimal dose of CUDC-427 in combination with the standard capecitabine regimen. In addition, the company also plans to examine CUDC-427 for the treatment of aggressive lymphomas as well as certain indolent lymphomas such as MALT lymphomas.

About the Phase 1 Dose Escalation Trial

This Phase 1, open-label, multicenter study is designed to determine the MTD and recommended Phase 2 dose of oral CUDC-427 administered as a single agent twice-daily on a continuous daily schedule for a 21-day cycle in patients with advanced and refractory solid tumors or lymphomas. The secondary objectives of the study are to assess CUDC-427's safety and tolerability, pharmacokinetics, exploratory biomarkers of activity and preliminary anti-cancer activity. Patients will be dose escalated according to the standard 3+3 design with a starting dose of 400 mg/day (200 mg BID) and escalated at increments of 200 mg/day. Upon determination of MTD or the recommended Phase 2 dose, the trial is designed to enroll up to an additional 12 patients in the expansion cohort of a particular cancer type, primarily ovarian and fallopian tube cancers.

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs